Significant EU funding for international AICCELERATE consortium proposing a scalable AI tool for smart hospital
14.12.2020 10:39:49 EET | HUS | Press release
The AICCELERATE consortium consists of specialists in the fields of IT, machine learning, robotics, neurology, paediatrics and surgery from Finland, Italy, Spain, Turkey, Netherlands, Germany and Belgium.
Healthcare systems lack flexible AI solutions that allow hospitals to improve efficiency and the quality of patient care. Current solutions provide limited scalability and are confined to isolated applications. Scalable models that address data sharing, integration, privacy, and ethics are needed to ensure better adoption of AI in healthcare. Patient empowerment and evidence-based trust towards AI is a key part of the project. Evaluation activities will also focus on cost-benefit analysis of the AI-solutions.
AICCELERATE will develop partners’ existing digital solutions further to enable the development of a Smart Hospital Care Pathway (SHCP) Engine. This engine serves as a toolset for AI models and robotics to improve quality of care and health outcomes. It will also enable lean management and effective decision-making.
These tools are tested in three pilots that will provide feedback for improving the SHCP Engine: (i) patient flow management for ER and surgical units, (ii) digital care pathway for Parkinson’s disease, and (iii) paediatric service delivery.
The pilots are carried out by 5 hospital partners: Helsinki University Hospital and Oulu University Hospital from Finland, Ospedale Pediatrico Bambino Gesù from Italy, Barcelona Children's Hospital from Spain, and University Hospital Università degli Studi di Padova from Italy.
In addition to these above mentioned hospitals The AICCELERATE consortium is formed by Erasmus Univ. Rotterdam from Netherlands, RTO Fundació Eurecat from Spain, a Spanish non-profit TICBioMed, 6 SMEs aiming to advance the digitalization of the European healthcare services: Chino from Italy, Symptoma from Austria, Nuromedia from Germany, SRDC from Turkey, Evondos from Finland, NeuroPath from Belgium, and 2 large enterprises NEC Laboratories Europe from Germany and Innofactor from Finland. The preparation of the proposal was supported by Spinverse from Finland.
Keywords
Contacts
More information:
Development Manager Tuuli Pajunen
tuuli.pajunen@hus.fi, +358 40 182 5028
Research and Innovation Manager Suzan Ikävalko,
suzan.ikavalko@hus.fi, +358 50 583 4292
Images
About HUS
At HUS Helsinki University Hospital about 680 000 patients receive medical care annually. We have almost 27,000 professionals working for the best of all patients. We are responsible for providing specialized health care for the residents of our 24 member municipalities. In addition, the treatment of many rare and severe diseases is nationally centralized to HUS.
HUS is the biggest health care provider and the second largest employer in Finland. Our expertise is internationally recognized and accredited. As a university hospital, we continuously develop and evaluate our treatment methods and activities.
Subscribe to releases from HUS
Subscribe to all the latest releases from HUS by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from HUS
Mekanismerna bakom ruptur av hjärnaneurysm preciseras – HUS medverkar i en internationell studie6.7.2026 07:39:02 EEST | Pressmeddelande
HUS Helsingfors universitetssjukhus medverkar i en internationell studie som tillför ny information om varför en del hjärnaneurysm rupturerar. Resultaten kan i framtiden bidra till att bättre än i nuläget identifiera aneurysmen med störst rupturrisk och stödja utvecklingen av nya läkemedelsbehandlingar. Studien har publicerats i den ansedda tidskriften Nature Neuroscience.
Aivovaltimopullistuman puhkeamisen mekanismi tarkentuu – HUS mukana kansainvälisessä tutkimuksessa6.7.2026 07:39:02 EEST | Tiedote
HUS Helsingin yliopistollinen sairaala oli mukana kansainvälisessä tutkimuksessa, joka tuo uutta tietoa siihen, miksi osa aivovaltimopullistumista puhkeaa. Tulokset voivat tulevaisuudessa auttaa tunnistamaan nykyistä paremmin ne pullistumat, joiden puhkeamisriski on suurin ja tukemaan uusien lääkehoitojen kehittämistä. Tutkimus on julkaistu arvostetussa Nature Neuroscience -lehdessä.
Arbetet för babyvänlig verksamhet fortsätter – utvecklingsarbetet fortsätter med ny sammansättning2.7.2026 10:28:59 EEST | Pressmeddelande
Efter att Institutet för hälsa och välfärd THL:s nationella samordnande upphörde fortsätter arbetet för babyvänlig verksamhet i samarbete med alla välfärdsområden. Målet för den sakkunniggrupp som HUS har sammankallat är att trygga och utveckla babyvänlig vård i hela landet.
Vauvamyönteinen työ jatkuu – kehittämistyö jatkuu uudella kokoonpanolla2.7.2026 10:28:59 EEST | Tiedote
THL:n kansallisen koordinaation päätyttyä vauvamyönteisyystyö jatkuu yhteistyössä kaikkien hyvinvointialueiden kanssa. HUSin koollekutsuman asiantuntijaryhmän tavoitteena on turvata ja kehittää vauvamyönteistä hoitoa koko maassa.
Blodprov underlättar diagnostiken av lymfkörtelinflammationer i halsområdet hos barn1.7.2026 08:54:42 EEST | Pressmeddelande
En studie som genomförts vid HUS har bekräftat tillförlitligheten hos en blodprovsbaserad diagnostisk metod för lymfkörtelinflammationer i halsområdet hos barn som orsakas av miljömykobakterier. Ett blodprov är ett snabbare och för patienten mer skonsamt sätt att säkerställa diagnosen än invasiva metoder, såsom vävnadsprovtagning.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom